Y-mAbs Therapeutics (YMAB) Tops Q2 EPS by 19c

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.07), $0.19 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $19.53 million versus the consensus estimate of $18.37 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Cleveland-Cliffs plans $1B upgrade at Middletown Works steel plant
• Popular stocks: HOOD MSTR MU BABA SPCX SOFI COIN PLTR MRNA INTC AVGO